Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.49 |
| ▸ | THPO | P40225 | 3/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5387586 | 0.98 | EGFR (0.47) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL30666111 | 0.98 | EGFR (0.47) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL3675298 | 0.78 | CA2 (0.42) | ALDH1A1HIF1ALMNASMN1; SMN2MAPT | |
| SCHEMBL8599765 | 0.78 | KMT2A (0.48) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL30271295 | 0.77 | ALDH1A1 (0.54) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL6323846 | 0.77 | APP (0.41) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL1269424 | 0.76 | CYP3A4 (0.54) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL5987618 | 0.76 | EGFR (0.44) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL1837511 | 0.76 | ESRRG (0.55) | EGFRERBB2ALDH1A1HIF1ALMNA | |
| SCHEMBL14714244 | 0.76 | HDAC6 (0.45) | EGFRERBB2ALDH1A1HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | claimed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | claimed |
| EP-4320124-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2024-02-14 | — | — | EP | claimed |
| EP-4313156-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2024-02-07 | — | — | EP | claimed |
| CN-109574960-B | Docetaxel derivative and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| WO-2022214598-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-4071148-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2022-10-12 | — | — | EP | claimed |
| WO-2022200347-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | claimed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | EGFR 1387/4885ERBB2 2584/4885ALDH1A1 1189/4885 |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | EGFR 3386/4885ERBB2 3004/4885ALDH1A1 245/4885 |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | DHCR7, DECR1, CYP27A1 | EGFR 3676/4885ERBB2 3162/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.